The latest group includes several firm developing genomics tools or diagnostics, but COVID-19 is preventing them from accessing their lab space for the time being.
The accelerated approval is based on data showing that refractory cancer patients with TMB of at least 10 mutations/Mb saw tumor shrinkage and had durable responses on the immunotherapy.
The sequencing instrument developer is in the process of scaling and optimizing its silicon chips and plans to offer its platform by the end of next year.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
